Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line

E. Rabizadeh; V. Merkin; I. Belyaeva; M. Shaklai; Y. Zimra

doi:10.1016/j.leukres.2006.12.015

Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line

E. Rabizadeh^*
, V. Merkin
, I. Belyaeva
, M. Shaklai
, Y. Zimra

^*Corresponding author for this work

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is associated with the high TK activity chimeric protein BCR-ABL, known to contribute to cell tumorogenicity, resistance to apoptosis and differentiation. STI571, the TK inhibitor, is the current treatment for CML. One possible approach to overcome STI571 resistance appearing in some cases, involves the combination of histone deacetylase inhibitors (HDI) and STI571. We demonstrated that in K562, the CML cell line, pivaloyloxymethyl butyrate (Pivanex)-induced apoptosis, differentiation and reduced BCR-ABL protein levels and that the combination of Pivanex with STI571 acted synergistically. These data suggest the possible benefit of combining this HDI with STI571 for treatment of CML.

Original language	English
Pages (from-to)	1115-1123
Number of pages	9
Journal	Leukemia Research
Volume	31
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2006.12.015
State	Published - Aug 2007
Externally published	Yes

Funding

Funders
Dalia Gredinger Foundation

Keywords

Apoptosis
BCR-ABL
CML
HDI
Pivanex

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2006.12.015

Cite this

@article{8b891234ecdc48789748eabf479a238a,

title = "Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line",

abstract = "Chronic myelogenous leukemia (CML) is associated with the high TK activity chimeric protein BCR-ABL, known to contribute to cell tumorogenicity, resistance to apoptosis and differentiation. STI571, the TK inhibitor, is the current treatment for CML. One possible approach to overcome STI571 resistance appearing in some cases, involves the combination of histone deacetylase inhibitors (HDI) and STI571. We demonstrated that in K562, the CML cell line, pivaloyloxymethyl butyrate (Pivanex)-induced apoptosis, differentiation and reduced BCR-ABL protein levels and that the combination of Pivanex with STI571 acted synergistically. These data suggest the possible benefit of combining this HDI with STI571 for treatment of CML.",

keywords = "Apoptosis, BCR-ABL, CML, HDI, Pivanex",

author = "E. Rabizadeh and V. Merkin and I. Belyaeva and M. Shaklai and Y. Zimra",

note = "Funding Information: This work was supported in part by a Grant from the Dalia Gredinger Foundation. We thank Mrs. Sara Dominitz for her editorial assistance.",

year = "2007",

month = aug,

doi = "10.1016/j.leukres.2006.12.015",

language = "אנגלית",

volume = "31",

pages = "1115--1123",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "8",

}

TY - JOUR

T1 - Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line

AU - Rabizadeh, E.

AU - Merkin, V.

AU - Belyaeva, I.

AU - Shaklai, M.

AU - Zimra, Y.

N1 - Funding Information: This work was supported in part by a Grant from the Dalia Gredinger Foundation. We thank Mrs. Sara Dominitz for her editorial assistance.

PY - 2007/8

Y1 - 2007/8

N2 - Chronic myelogenous leukemia (CML) is associated with the high TK activity chimeric protein BCR-ABL, known to contribute to cell tumorogenicity, resistance to apoptosis and differentiation. STI571, the TK inhibitor, is the current treatment for CML. One possible approach to overcome STI571 resistance appearing in some cases, involves the combination of histone deacetylase inhibitors (HDI) and STI571. We demonstrated that in K562, the CML cell line, pivaloyloxymethyl butyrate (Pivanex)-induced apoptosis, differentiation and reduced BCR-ABL protein levels and that the combination of Pivanex with STI571 acted synergistically. These data suggest the possible benefit of combining this HDI with STI571 for treatment of CML.

AB - Chronic myelogenous leukemia (CML) is associated with the high TK activity chimeric protein BCR-ABL, known to contribute to cell tumorogenicity, resistance to apoptosis and differentiation. STI571, the TK inhibitor, is the current treatment for CML. One possible approach to overcome STI571 resistance appearing in some cases, involves the combination of histone deacetylase inhibitors (HDI) and STI571. We demonstrated that in K562, the CML cell line, pivaloyloxymethyl butyrate (Pivanex)-induced apoptosis, differentiation and reduced BCR-ABL protein levels and that the combination of Pivanex with STI571 acted synergistically. These data suggest the possible benefit of combining this HDI with STI571 for treatment of CML.

KW - Apoptosis

KW - BCR-ABL

KW - CML

KW - HDI

KW - Pivanex

UR - https://www.scopus.com/pages/publications/34249994385

U2 - 10.1016/j.leukres.2006.12.015

DO - 10.1016/j.leukres.2006.12.015

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:34249994385

SN - 0145-2126

VL - 31

SP - 1115

EP - 1123

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this